 
 |
|
Arena Pharmaceuticals' Lorcaserin Reduces Body Weight and Improves Cardiovascular Risk Factors Across Patient Subgroups
Date: June 26, 2010
Client: Arena Pharmaceuticals, Inc.
Summary: ORLANDO, Fla., June 26, 2010 /PRNewswire via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today reported pooled Week 52 data from more than 6,000 patients in lorcaserin's pivotal Phase 3 clinical trial program that demonstrate lorcaserin 10 mg dosed twice daily reduced body weight in all patient subgroups evaluated, as defined by gender, age, ethnicity and starting body weight and Body Mass Index (BMI). Greater improvements in cardiovascular risk factors were also achieved with lorcaserin treatment compared to placebo overall and in most subgroups.
|
|
|
|
 |
|
Doctors, Depression, and DNA
Date: June 25, 2010
Client: AssureRx Health, Inc.
Summary: Psychiatrists call it the “trial and error factor”: when they set out to prescribe an antidepressant, they have no clinically proven way of knowing which one to choose. Any given antidepressant tends to help only about a third of patients; the other two-thirds end up doing the prescription shuffle, trying one drug, then another, then a third or fourth in hopes of finally hitting on a treatment that works.
|
|
|
|
 |
|
sanofi-aventis and Regulus Therapeutics Form Major Strategic Alliance on microRNA Therapeutics
Date: June 22, 2010
Client: Regulus Therapeutics Inc.
Summary: Carlsbad, CA., June 22, 2010 – Regulus Therapeutics Inc. and sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that they have entered into a global, strategic alliance to discover, develop, and commercialize microRNA therapeutics. The alliance represents the largest microRNA partnership formed to date, valued at potentially over $750 million, and includes a $25 million upfront fee, a $10 million future equity investment subject to mutual agreement on company valuation, and annual research support for three years with the option to extend two additional years. The alliance will initially focus on the therapeutic area of fibrosis. Regulus and sanofi-aventis will collaborate on up to four microRNA targets, including Regulus’ lead fibrosis program targeting microRNA-21. sanofi-aventis also receives an option for a broader technology alliance that provides Regulus certain rights to participate in development and commercialization of resulting products. If exercised, this three-year option is worth an additional $50 million to Regulus.
|
|
|
|
 |
|
Positive Phase 2 Data on RDEA594, Ardea Biosciences' Lead Product Candidate for the Treatment of Hyperuricemia and Gout, Presented at the Annual European Congress of Rheumatology
Date: June 18, 2010
Client: Ardea Biosciences, Inc.
Summary: ROME, ITALY, June 18, 2010 -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced that additional positive data from its Phase 2 program for RDEA594, its lead product candidate for the treatment of hyperuricemia and gout, are being presented at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism (EULAR) in Rome, Italy. RDEA594, a first-in-class selective inhibitor of the URAT1 transporter, treats the underlying cause of gout by increasing the excretion of uric acid in order to bring the body’s levels of uric acid into a normal range.
|
|
|
|
 |
|
New Data for Investigational Antibody Blocking IL-6 in Rheumatoid Arthritis Patients to be Presented at Annual Congress of European League Against Rheumatism
Date: June 16, 2010
Client: Alder Biopharmaceuticals
Summary: ROME (June 16, 2010) -- Bristol-Myers Squibb Company (NYSE:BMY) and Alder Biopharmaceuticals today announced that new data from a dose-ranging Phase 2a trial support further development of BMS-945429/ALD518, an investigational monoclonal antibody directed against interleukin-6 (IL-6), as a potential treatment for rheumatoid arthritis (RA). The Phase 2a data will be presented in a scientific session on June 18, 2010, at the Annual Congress of the European League against Rheumatism (EULAR).
|
|
|
|
 |
|
Promega and Cellular Dynamics Partner to Validate Stem Cell-Based In Vitro Assays for Predicting Drug-Induced Cardiotoxicity
Date: June 15, 2010
Client: Cellular Dynamics International
Summary: MADISON, Wis.--(BUSINESS WIRE)--Cellular Dynamics International (CDI) and Promega have entered into a research collaboration with the goal of bringing more relevant and highly predictive toxicity testing to the drug discovery process. Pharmaceutical discovery scientists will now be able to combine bioassays with human cardiomyocytes to improve prediction of unintentional, detrimental side effects that have previously remained undetected until late in the development process or after release of the drug to the general public.
|
|
|
|
 |
|
MedAssurant's Prospective Advantage™ Solution Selected by Blue Cross and Blue Shield of Minnesota
Date: June 14, 2010
Client: MedAssurant, Inc.
Summary: BOWIE, Md. – June 14, 2010 – MedAssurant, Inc., a leading technology-enabled healthcare solutions provider, today announced that Blue Cross and Blue Shield of Minnesota has selected Prospective Advantage™ to identify and close gaps in assessment, documentation, and quality of care within its Dual-Eligible Special Needs plans.
|
|
|
|
 |
|
S*BIO Presents Positive Safety and Tolerability Results for its Novel Oral JAK2 Inhibitor SB1518 from a Phase 1/2 Study for the Treatment of Myelofibrosis (MF)
Date: June 13, 2010
Client: S*BIO
Summary: Singapore, June 13, 2010 - S*BIO Pte Ltd today announced the presentation of positive safety, tolerability and pharmacokinetic/pharmacodynamic (PK/PD) results for its novel oral JAK2 inhibitor, SB1518, at the 15th Congress of the European Hematology Association (EHA), June 10-13, in Barcelona, Spain.
|
|
|
|
 |
|
Otonomy Closes $10 Million Series A Financing
Date: June 11, 2010
Client: Otonomy, Inc.
Summary: SAN DIEGO, June 11, 2010 – Otonomy, Inc. announced today that it has completed a $10 million Series A financing with Avalon Ventures. Proceeds from the financing will be used to support the ongoing clinical trial for OTO-104 in Ménière’s disease, initiate IND-enabling studies for OTO-203, and continue early-stage development of a third program.
|
|
|
|
|
|
S*BIO Completes Enrollment of Patients in Phase 2 Clinical Trials for its JAK2 Inhibitor SB1518
Date: June 9, 2010
Client: S*BIO
Summary: Singapore, June 9, 2010 - S*BIO Pte Ltd today announced that it has completed enrollment of patients in two separate Phase 2 clinical trials for its potent and orally-active JAK2 inhibitor SB1518 at multiple clinical sites in the U.S. and Australia for the treatment of myelofibrosis (MF). Insert Summary here
|
|
|
|
 |
|
Helix BioPharma Corp Announces Phase II Clinical Trial Results of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
Date: June 8, 2010
Client: Helix BioPharma Corp.
Summary: AURORA, Ontario, June 8 /PRNewswire-FirstCall/ -- Helix BioPharma Corp. (TSX, FSE: "HBP" / OTCQX: HXBPF) today announced results from the Phase II clinical trial assessing the efficacy and safety of Topical Interferon Alpha-2b cream for the treatment of ano-genital warts (AGW).
|
|
|
|
 |
|
AMDeC Launches First-Ever, Real-Time Online Database of Biomedical Research Technology and Resources Available in New York
Date: June 8, 2010
Client: AMDec
Summary: NEW YORK, June 8, 2010 – AMDeC, the Academy for Medical Development and Collaboration, today announced the launch of AMDeC F.I.R.S.T. (Facilities Instrumentation Resources Services Technologies), the first-ever comprehensive, real-time online registry and database of biomedical research technology and resources, now available for New York. With this new online Web-resource, researchers will not be limited by the core facilities offered at their own institution, but rather they will be able to review and to use the innovative technology resources hosted at what will soon be over 100 core facilities throughout the state. Biotech and pharmaceutical companies will also be able to purchase a subscription to AMDeC F.I.R.S.T. in order to identify biomedical resources available on a fee-for-service basis.
|
|
|
|
 |
|
Phase 2b Clinical Trial Results Show Aerovance's Aerovant™ is Effective in Patients with Eosinophilic Asthma
Date: June 8, 2010
Client: Aerovance Inc.
Summary: BERKELEY, Calif., June 8 /PRNewswire/ -- Aerovance Inc. today announced top-line results from its Phase 2b clinical trial that show the inhaled dry powder formulation of Aerovant (pitrakinra inhalation powder) is effective in a pre-defined subset of patients with eosinophilic asthma.
|
|
|
|
|
|
Alder Biopharmaceuticals’ ALD518 Antibody Therapeutic Reduces Disease Symptoms, Anemia in Phase 2a Clinical Trial in Non-Small Cell Lung Cancer Patients
Date: June 6, 2010
Client: Alder Biopharmaceuticals Inc.
Summary: CHICAGO, June 6, 2010 – Alder Biopharmaceuticals Inc. today announced that patients with late-stage non-small cell lung cancer (NSCLC) showed improvement in cancer-related anemia and symptoms of the disease in a Phase 2a clinical trial of ALD518, a monoclonal antibody directed against interleukin-6 (IL-6). Insert Summary here
|
|
|
|
|
